Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Cash & Equivalents (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Cash & Equivalents of $141.9 million for Q4 2025, down 69.46% on a QoQ basis from $464.5 million in Q4 2024, and down 69.46% year-over-year from $464.5 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Cash & Equivalents data on file, last reported at $141.9 million in Q4 2025.

  • In Q4 2025, Cash & Equivalents fell 69.46% year-over-year to $141.9 million; the TTM figure through Dec 2025 stood at $141.9 million (down 69.46% YoY), while the FY2025 annual figure was $141.9 million, down 67.76% from the prior year.
  • Cash & Equivalents fell to $141.9 million in Q4 2025, from $464.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $464.5 million in Q4 2024 and bottomed at $80.2 million in Q4 2023.
  • A 3-year average of $228.9 million and a median of $141.9 million in 2025 frame the typical range for Cash & Equivalents.
  • Annual changes were most pronounced in 2024 — Cash & Equivalents soared 479.03% — and 2025, when it slumped 69.46%.
  • Year by year, Cash & Equivalents stood at $80.2 million in 2023, then soared by 479.03% to $464.5 million in 2024, then slumped by 69.46% to $141.9 million in 2025.
  • The last three Cash & Equivalents figures came in at $141.9 million (Q4 2025), $464.5 million (Q4 2024), and $80.2 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 1.91 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 32.30 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 286.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 61.46 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 2.77 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.49 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 18.44 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 2.96 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.71 Bn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 141.87 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 141.87 Mn
Dec 31, 2024 464.54 Mn
Dec 31, 2023 80.23 Mn